Vicarious Surgical Q3 adjusted EPS beats expectations on lower expenses

Reuters11-13

<a href="https://laohu8.com/S/RBOT">Vicarious Surgical</a> Q3 adjusted EPS beats expectations on lower expenses

Overview

Vicarious Surgical Q3 adjusted EPS beats analyst expectations
Operating expenses decreased 35% yr/yr in Q3 2025
Company raised $5.9 mln in direct offering to support operations

Outlook

Company expects full year 2025 cash burn of approximately $50 mln

Result Drivers

COST REDUCTIONS - Operating expenses decreased 35% yr/yr due to reductions in R&D, G&A, and sales and marketing expenses
CAPITAL DISCIPLINE - CEO focuses on reducing burn rate while keeping development timelines on track
FUNDRAISING - Co raised $5.9 mln in direct offering to support operations and goals

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Adjusted EPS	Beat	-$1.91	-$2.33 (3 Analysts)
Q3 EPS		-$1.86
Q3 Adjusted Net Income	Beat	-$11.30 mln	-$14.43 mln (3 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Vicarious Surgical Inc is $10.00, about 54.3% above its November 11 closing price of $4.57

Press Release: ID:nBwdhV4ka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583583231?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583583231","market":"us","top_or_hot":-1,"title":"Vicarious Surgical Q3 adjusted EPS beats expectations on lower expenses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/RBOT\">Vicarious Surgical</a> Q3 adjusted EPS beats expectations on lower expenses</title></head><body><p><span>Overview</span></p><ul><li><p>Vicarious Surgical Q3 adjusted EPS beats analyst expectations</p></li><li><p>Operating expenses decreased 35% yr/yr in Q3 2025</p></li><li><p>Company raised $5.9 mln in direct offering to support operations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects full year 2025 cash burn of approximately $50 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COST REDUCTIONS - Operating expenses decreased 35% yr/yr due to reductions in R&amp;D, G&amp;A, and sales and marketing expenses</p></li><li><p>CAPITAL DISCIPLINE - CEO focuses on reducing burn rate while keeping development timelines on track</p></li><li><p>FUNDRAISING - Co raised $5.9 mln in direct offering to support operations and goals</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$1.91</p></td><td><p>-$2.33 (3 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$1.86</p></td><td></td></tr><tr><td><p>Q3 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$11.30 mln</p></td><td><p>-$14.43 mln (3 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Vicarious Surgical Inc is $10.00, about 54.3% above its November 11 closing price of $4.57</p></li></ul><p>Press Release: <span>ID:nBwdhV4ka</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vicarious Surgical Q3 adjusted EPS beats expectations on lower expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVicarious Surgical Q3 adjusted EPS beats expectations on lower expenses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/RBOT\">Vicarious Surgical</a> Q3 adjusted EPS beats expectations on lower expenses</title></head><body><p><span>Overview</span></p><ul><li><p>Vicarious Surgical Q3 adjusted EPS beats analyst expectations</p></li><li><p>Operating expenses decreased 35% yr/yr in Q3 2025</p></li><li><p>Company raised $5.9 mln in direct offering to support operations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects full year 2025 cash burn of approximately $50 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COST REDUCTIONS - Operating expenses decreased 35% yr/yr due to reductions in R&amp;D, G&amp;A, and sales and marketing expenses</p></li><li><p>CAPITAL DISCIPLINE - CEO focuses on reducing burn rate while keeping development timelines on track</p></li><li><p>FUNDRAISING - Co raised $5.9 mln in direct offering to support operations and goals</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$1.91</p></td><td><p>-$2.33 (3 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$1.86</p></td><td></td></tr><tr><td><p>Q3 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$11.30 mln</p></td><td><p>-$14.43 mln (3 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Vicarious Surgical Inc is $10.00, about 54.3% above its November 11 closing price of $4.57</p></li></ul><p>Press Release: <span>ID:nBwdhV4ka</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RBOT","symbol_name":"Vicarious Surgical Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO15J:1","article_id":"2583583231","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583583231","pubTimestamp":1762982947,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vicarious Surgical Q3 adjusted EPS beats expectations on lower expensesOverviewVicarious Surgical Q3 adjusted EPS beats analyst expectationsOperating expenses decreased 35% yr/yr in Q3 2025Company rai","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RBOT":"Vicarious Surgical Inc.","BK4082":"医疗保健设备"},"translate_title":"Vicarious Surgical第三季度调整后每股收益因费用降低而超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RBOT":0.9},"content_text":"Vicarious Surgical Q3 adjusted EPS beats expectations on lower expensesOverviewVicarious Surgical Q3 adjusted EPS beats analyst expectationsOperating expenses decreased 35% yr/yr in Q3 2025Company raised $5.9 mln in direct offering to support operationsOutlookCompany expects full year 2025 cash burn of approximately $50 mlnResult DriversCOST REDUCTIONS - Operating expenses decreased 35% yr/yr due to reductions in R&D, G&A, and sales and marketing expensesCAPITAL DISCIPLINE - CEO focuses on reducing burn rate while keeping development timelines on trackFUNDRAISING - Co raised $5.9 mln in direct offering to support operations and goalsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Adjusted EPSBeat-$1.91-$2.33 (3 Analysts)Q3 EPS-$1.86Q3 Adjusted Net IncomeBeat-$11.30 mln-$14.43 mln (3 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy.\"Wall Street's median 12-month price target for Vicarious Surgical Inc is $10.00, about 54.3% above its November 11 closing price of $4.57Press Release: ID:nBwdhV4kaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583583231","isCrawlerRequest":true}